Astria Therapeutics’ (ATXS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS) in a research report released on Thursday,Benzinga reports. HC Wainwright currently has a $16.00 price target on the biotechnology company’s stock.

Separately, Oppenheimer lifted their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Astria Therapeutics currently has an average rating of “Buy” and an average target price of $25.60.

Astria Therapeutics Trading Down 1.9 %

ATXS opened at $7.41 on Thursday. Astria Therapeutics has a 1-year low of $7.16 and a 1-year high of $16.90. The firm’s 50 day simple moving average is $9.12 and its two-hundred day simple moving average is $10.57. The company has a market capitalization of $418.18 million, a PE ratio of -3.55 and a beta of 0.70.

Institutional Trading of Astria Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ATXS. Dimensional Fund Advisors LP boosted its position in shares of Astria Therapeutics by 1,043.7% during the second quarter. Dimensional Fund Advisors LP now owns 146,158 shares of the biotechnology company’s stock worth $1,330,000 after acquiring an additional 133,379 shares during the last quarter. Hsbc Holdings PLC bought a new position in shares of Astria Therapeutics during the 2nd quarter valued at about $171,000. Cubist Systematic Strategies LLC purchased a new position in shares of Astria Therapeutics during the second quarter valued at about $2,561,000. Millennium Management LLC increased its holdings in shares of Astria Therapeutics by 13.5% in the second quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock worth $16,763,000 after purchasing an additional 218,518 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in shares of Astria Therapeutics in the second quarter worth about $400,000. Institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.